Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company dedicated to advancing medical treatments for Parkinson's disease and related disorders. Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase focuses primarily on the development of protein kinase inhibitors to modify the course of neurodegenerative diseases.
The company's flagship product candidate, IkT-148009, is a selective inhibitor of the non-receptor Abelson Tyrosine Kinases aimed at treating Parkinson's disease both inside and outside the brain. IkT-148009 is also being explored for its potential in treating dysphagia and neurogenic constipation, conditions often associated with Parkinson's disease.
Another noteworthy product in Inhibikase's pipeline is IkT-001Pro, a prodrug of the anti-cancer agent imatinib. Currently in preclinical development, IkT-001Pro aims to minimize gastrointestinal side effects commonly seen in cancer treatments. The company is also developing IkT-01427, which targets the causative virus of progressive multifocal leukoencephalopathy, and the IkT-148x series, meant for treating dementia with Lewy bodies and multiple system atrophy.
In recent news, Inhibikase announced that it would host a conference call on March 28, 2024, to discuss its latest developments. Furthermore, the company is reviewing IkT-001Pro's potential as a disease-modifying treatment for Pulmonary Arterial Hypertension. Financially, the company reported $2.8 million in research and development expenses and $2.0 million in selling, general, and administrative expenses for the quarter ended March 31, 2024.
For more information, you can contact the company through Milton H. Werner, PhD, President & CEO, at 678-392-3419 or via email at info@inhibikase.com. Investor relations are handled by Alex Lobo at Stern Investor Relations, Inc.
On May 10, 2022, Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner, President & CEO, will present at the H.C. Wainwright Global Investment Conference in Miami Beach, FL, scheduled for May 25, 2022 at 2:30 pm ET. The company is focused on developing therapies for Parkinson's disease and related disorders, with a lead program targeting the treatment of neurodegeneration. Inhibikase's multi-therapeutic pipeline includes IkT-148009 and other drug delivery technologies, aimed at enhancing patient experience.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) will report its first-quarter 2022 financial results on May 16, 2022, after U.S. market close. A conference call will follow on May 17, 2022, at 8:00 a.m. ET to discuss the results and provide a corporate update. The company focuses on developing therapeutics for Parkinson's disease and related disorders, with its lead program targeting neurodegeneration. Investors can access the call through specified phone numbers or via a live webcast.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced Dr. Milton Werner will participate in a fireside chat at B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 2:30 PM ET. A live webcast will be available for on-demand viewing on the company's website, with an archival replay accessible for 30 days. The company focuses on developing therapeutics for Parkinson's disease, notably its lead program IkT-148009, aimed at treating the disease both in the brain and gastrointestinal tract.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) will host a virtual KOL investor event on April 20, 2022, at 10:00 am ET. The event will feature presentations from the executive leadership team and key opinion leaders, including Dr. Robert F. Hauser and Dr. Werner Poewe. They will discuss data from Phase 1 and 1b studies of IkT-148009, the company's lead candidate for Parkinson's disease treatment, and outline the upcoming Phase 2 program. A live webcast will be available on the company’s website, with a replay accessible for 90 days.
Inhibikase Therapeutics (Nasdaq: IKT) reported its 2021 financial results, noting a net loss of $14.8 million, or $0.81 per share, compared to $2.8 million, or $0.35 per share, in 2020. Grant revenue surged to $3.1 million from $0.7 million, driven by increased research activity. The company emphasized the successful advancement of its lead program, IkT-148009, into clinical trials for Parkinson's disease. The Phase 1b study showed a favorable safety profile, and a Phase 2a trial is anticipated to start in Q2 2022. Cash reserves stood at $40.8 million, sufficient until Q3 2023.
Inhibikase Therapeutics (Nasdaq: IKT) will present at the Next Generation Kinase Inhibitors Summit from March 29-31, 2022. Dr. Milton Werner, President & CEO, will discuss the biochemical processes linked to Parkinson's disease and the lead c-Abl inhibitor, IkT-148009. His presentation, titled "Providing the First Mechanistic Basis for Halting Neurodegenerative Disease: Targeting c-Abl to Reverse Parkinson's Disease," is scheduled for March 31 at 9:30 a.m. EDT in Boston. The event is free for registrants, and Dr. Werner will summarize clinical data from ongoing Phase 1/1b trials of IkT-148009.
Inhibikase Therapeutics (Nasdaq: IKT) will disclose its financial results for the full year ended December 31, 2021, on March 31, 2022. The announcement will be followed by a conference call and webcast on April 1, 2022, at 8:00 a.m. ET, where the company will provide a corporate update. Inhibikase is focused on developing therapeutics aimed at modifying the course of Parkinson's disease and related disorders, with its lead program targeting the disease both in the brain and gastrointestinal tract.
Inhibikase Therapeutics (Nasdaq: IKT), a clinical-stage pharmaceutical firm focusing on Parkinson's disease, announced that Dr. Milton Werner will present at the Maxim Group 2022 Virtual Growth Conference from March 28 to 30. The presentation will be available for on-demand viewing starting March 28 at 9:00 AM ET on the company's website. Inhibikase is advancing therapeutics targeting neurodegenerative disorders, including its leading program IkT-148009, aimed at treating Parkinson's disease and related conditions.
Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner will present at the AD/PD™ Conference in Barcelona from March 15-20, 2022. The presentation will cover results from preclinical and Phase 1 studies of IkT-148009, a selective Abelson Tyrosine Kinase inhibitor for Parkinson's disease. Results indicate IkT-148009 clears alpha-synuclein aggregates, protects neurons, and shows no significant adverse events across 88 subjects. The company plans to initiate a Phase 2 study in Q2 2022, further validating the therapeutic potential of IkT-148009 as a disease-modifying treatment.
Inhibikase Therapeutics (Nasdaq: IKT) reported significant milestones and goals for 2022, focusing on Parkinson's disease therapies, particularly IkT-148009. Key developments include continuing Phase 1 dosing studies in healthy volunteers and patients, completing chronic toxicology data submissions to the FDA, and initiating Phase 2a clinical studies for IkT-148009. The company also aims to advance IkT-001Pro for Chronic Myelogenous Leukemia. Inhibikase's President highlighted the transformative year of 2021 and expressed optimism for 2022's advancements in treating neurodegenerative diseases.
FAQ
What is the current stock price of Inhibikase Therapeutics (IKT)?
What is the market cap of Inhibikase Therapeutics (IKT)?
What does Inhibikase Therapeutics, Inc. specialize in?
What is IkT-148009?
What is the purpose of IkT-001Pro?
Where is Inhibikase Therapeutics headquartered?
When was Inhibikase Therapeutics founded?
What other products are in Inhibikase's pipeline?
Who is the President & CEO of Inhibikase Therapeutics?
How can I contact Inhibikase Therapeutics for more information?
What are the latest financial figures for Inhibikase?
When is the next company conference call?
